OncoMatch/Clinical Trials/NCT05319314
LYL273 for Patients With Relapsed or Refractory mCRC
Is NCT05319314 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies LYL273 for colorectal cancer.
Treatment: LYL273 — This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Allowed: KRAS wild-type
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with NCCN guidelines
Allowed: NRAS wild-type
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with NCCN guidelines
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine-based chemotherapy — advanced or metastatic
Received prior therapy with fluoropyrimidine-based chemotherapy in the advanced or metastatic setting
Must have received: oxaliplatin-based chemotherapy — advanced or metastatic
Received prior therapy with oxaliplatin-based chemotherapy in the advanced or metastatic setting
Must have received: irinotecan-based chemotherapy — advanced or metastatic
Received prior therapy with irinotecan-based chemotherapy in the advanced or metastatic setting
Must have received: anti-vascular endothelial growth factor (anti-VEGF) biological therapy — advanced or metastatic
an anti-vascular endothelial growth factor (anti-VEGF) biological therapy if not contraindicated
Must have received: anti-epidermal growth factor receptor (anti-EGFR) therapy — advanced or metastatic
if RAS wild-type an anti-epidermal growth factor receptor (anti-EGFR) therapy in a manner consistent with NCCN guidelines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- University of California San Francisco Medical Center · San Francisco, California
- University of Colorado Hospital - Anschutz Cancer Pavilion · Aurora, Colorado
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05319314 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received fluoropyrimidine-based chemotherapy and oxaliplatin-based chemotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages